Background--Results from observational and genetic epidemiological studies suggest that lower serum homocysteine levels are associated with lower incidence of cardiovascular disease (CVD). Numerous randomized controlled trials have investigated the efficacy of lowering homocysteine with folic acid supplementation for CVD risk, but conflicting results have been reported.
M
cCully postulated in 1969 that homocysteine affected atherosclerotic processes. 1 Since that time, prospective observations and genetic studies have suggested a causal role of blood homocysteine in the development of cardiovascular disease (CVD). [2] [3] [4] [5] [6] Observational studies indicated that for each 5-lmol/L rise in serum homocysteine levels, there was a 32% increased risk of ischemic heart diseases and a 59% increased risk of stroke. 4 The potential causal role of homocysteine in CVD was supported by Mendelian randomization studies using the gene encoding methylenetetrahydrofolate reductase (MTHFR), an enzyme involved in homocysteine metabolism, as an instrumental variable. Compared with people who were homozygous for the wild-type allele (CC) of MTHFR, those who were homozygous for the mutant allele (TT) had 1.93-lmol/L 5 or 25% 6 higher homocysteine concentrations, a 26% higher risk of stroke, 5 and a 16% higher risk of coronary heart disease (CHD). 6 Evidence from these studies provided the rationale for conducting randomized controlled trials (RCTs) of folic acid supplementation and CVD prevention, given that supplementation with folic acid is an inexpensive and effective method of lowering blood homocysteine concentrations. 7, 8 The introduction in 1998 of mandatory fortification of enriched cereal grain products with folic acid in North America, with the original impetus to reduce the occurrence of neural tube birth defects, 9 was associated with a significant reduction of the mean homocysteine concentration by %7% in middle-aged and older adults. 7 RCTs documented that daily dietary supplementation with 0.5 to 5 mg folic acid reduced plasma homocysteine concentrations by %25%. 8 The inconsistent results of the effects of folic acid supplementation on CVD risk called into question the causal relationship between increased homocysteine and CVD risk. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Several meta-analyses of RCTs have been conducted to summarize the available evidence, but the pooled
Patient Involvement
No patients were involved in setting the research question or the outcome measures or in the design and implementation of the study. There are no plans to involve patients in dissemination.
Data Extraction, Synthesis, and Methodological Quality Assessment
According to the standard protocol, all data from eligible trials were independently extracted in duplicate by 2 investigators (Y.L. and T.H.) and reviewed by a third investigator (Y.Z.). A predesigned data extraction form was used to extract relevant information. This included information on study design, baseline characteristics of participants, supplementation strategies, intervention effects on homocysteine and outcomes, mean age of participants at baseline (median if mean value not available), sex proportion, plasma folate and homocysteine levels at baseline, net changes and percentage changes of homocysteine before and after folic acid supplementation, the dosage of folic acid supplementation, intervention with and without other B vitamins, types of controls (placebo, usual care, untreated, or low dose of B vitamins), study location (countries) and mandatory folic acid fortification in the study location, preexisting disease status at baseline, the names of RCTs if available, and any systematically recorded outcomes that occurred during the scheduled treatment period (eg, events in intervention and control groups and reported hazard ratios). The risk of biases for each RCT (selection, performance, detection, attrition, reporting, and other biases) was assessed using the Cochrane risk-of-bias assessment tool 29 ; 7 criteria were evaluated. The risk of bias was rated as low, high, or unclear for each criterion. For each selected trial, net change in mean homocysteine was calculated as the change in mean homocysteine level from baseline to postintervention in the intervention group minus that change in the control group. Percentage change was defined as the net change divided by the mean baseline homocysteine level averaged across groups. If information on homocysteine was available only for the treatment group, 13, 30 net change was calculated as preintervention concentrations minus postintervention concentrations in the treatment group. For RCTs of factorial design, 13, 14, 31 participants receiving folic acid supplementation were compared with the placebo group if data on all factors were available in the publications 13, 31 ;
otherwise, all trial participants receiving folic acid supplementation were compared with all participants not receiving it regardless of other factorial interventions. 14 For trials with multiple publications 32, 33 at different follow-up periods, results for clinical outcomes with the longest follow-up from the primary publication were extracted. 33 Multivariate-adjusted relative risks (RRs) assessing the effects of folic acid supplementation on the risk of CVD, CHD, and/or stroke were extracted from each RCT if they were reported in the publications; otherwise, we calculated the RRs based on the number of events in each group. CHD events included nonfatal myocardial infarction and fatal coronary disease; stroke events included nonfatal and fatal stroke. The number of CVD events was obtained directly from the trial reports or as the composite of nonfatal myocardial infarction, nonfatal stroke, and vascular death. 
Meta-Analysis
We assessed the overall effect of folic acid supplementation on the risk of CVD, CHD, or stroke. RRs and corresponding standard errors were logarithmically transformed to stabilize variance and normalize the distribution. The inverse variance weighted method was used to combine summary measures using random-effects models to minimize the effects of between-study heterogeneity. Fixed-effect models were used in subsidiary analyses. We conducted stratified analyses by a number of factors, including duration of folic acid supplementation (<3 or ≥3 years), the magnitude of decrease in homocysteine concentration (<20%, 20-29.9%, or ≥30%), mandatory folic acid grain fortification (yes, partially, or no), folic acid with or without vitamin B6 or B12 (yes or no), control group with or without lowdose B vitamin (yes or no), preexisting renal disease status (yes or no), and CVD status (yes or no). For the stratified analysis by existing renal disease, we extracted data from the renal HOPE-2 study, 34 which was a post hoc analysis of a subgroup of participants who had renal diseases at baseline of the HOPE-2 trial. 17 The P value of the Cochrane Q statistic and I 2 index was used to evaluate between-study heterogeneity. 35 The potential for publication bias was evaluated by using Egger and Begg tests with funnel plots of the natural log of the RR versus its standard error. 36 Sensitivity analyses were done to assess the influence of each individual trial by omitting the trial that had the largest effect on the overall result one by one. All analyses were conducted using Stata 10 software (StataCorp LP). A 2-tailed P value of <0.05 was considered statistically significant.
Results
The initial literature search identified 1933 abstracts ( Figure 1 ). After screening based on titles and abstracts, 74
articles were selected for detailed evaluation of their full texts. Of those, 30 RCTs met our inclusion criteria and were included in our analysis. Tables 1 and 2 ).
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Characteristics of the Selected RCTs
The selected 30 RCTs enrolled 82 334 participants with a mean age of 50 years, and 53% were male. The average folic acid supplementation duration was 3.2 years (<2 years in 7 trials, 2-4 years in 18 trials, and ≥5 years in 5 trials). The (Tables 1 and 2 ). Sixteen trials enrolled participants with prior CVD, 10 trials included participants with renal diseases (chronic kidney disease, end-stage renal disease, or diabetes nephropathy), 1 included participants with hypertension, 26 1 included participants with atherosclerosis, 48 1 included participants with esophageal dysplasia, 38 and 1 included participants with history of colorectal adenomas. 46 Eighteen trials were conducted in nonfortified regions, 4 were conducted in partly fortified regions, and 8 were conducted in mandatorily fortified populations. Twenty trials applied folic acid supplementation only, and 10 trials applied folic acid supplementation in combination with vitamin B6 and/or B12. The control groups in 4 trials were treated with low-dose vitamin B, whereas another 26 trials used placebo or usual care for participants in the control group.
In considering the form of supplementation, only the SU.FOL.OM3 trial 14 from France used 5-methyltetrahydrofolate, and all others used folic acid. The change in homocysteine levels from the beginning to the end of the folic acid supplementation was reported in 23 trials (Table 1 ). All 23 trials showed a reduction in homocysteine levels, with net changes ranging from À1.5 to À26.0 lmol/L (percentage changes from À10.9% to 57.7%) ( Table 1) .
Effect of Folic Acid Supplementation on Risk of Stroke
In 20 trials, 3164 stroke events were reported among 77 816 participants (Figure 2 ). Across all 20 trials, the average incident rate for stroke was 3.8% (1509 events in 39 825 participants) in the folic acid supplementation group and 4.4% (1655 events in 37 911 participants) in the control group. Three individual studies observed a significantly reduced risk of stroke with supplementation of folic acid (Figure 2 The pooled RR for the 20 trials on stroke comparing folic acid supplementation with controls was 0.90 (95% CI 0.84-0.96, P=0.002) from the fixed-effect model and 0.88 (95% CI 0.80-0.98, P=0.02) from the random-effects model (Figure 2) .
Subgroup analyses revealed a more pronounced intervention effect among populations with lower baseline plasma folate levels (baseline folate <16 nmol/L in 7 RCTs: RR 0.79, 95% CI 0.69-0.89, P<0.0001; baseline folate ≥16 nmol/L in 7 RCTs: RR 0.97, 95% CI 0.86-1.08, P=0.57; P=0.02 for interaction) (Table 3 ). There was no evidence of heterogeneity in terms of significant intervention effects of folic acid supplementation on risk of stroke across other subgroups (all P>0.05 for interaction) ( Table 3 ).
Effect of Folic Acid Supplementation on Risk of CHD
In 25 trials, 5899 CHD events were reported among 78 192 participants ( Figure 3 ). Across all 25 trials, the average incidence rate for CHD was 7.7% (3091 events in 40 004 participants) in the folic acid supplementation group and 7.4% (2808 events in 38 188 participants) in the control group.
Only 1 individual study (Lange et al 41 ) observed a significantly increased risk of CHD with supplementation of folic acid ( Figure 3 ). The pooled RR for CHD comparing folic acid supplementation with the control group was 1.04 (95% CI 0.99-1.09, P=0.16) in both the fixed-and random-effects models ( Figure 3 ). The result did not differ significantly across subgroups (all P>0.15 for interaction) ( Table 3) .
Effect of Folic Acid Supplementation on Risk of CVD
In 22 trials, 8739 CVD events were reported among 74 346 participants ( Figure 4 ). Across all 22 trials, the average incident rate for CVD was 12.8% (4890 events in 38 097 participants) in the folic acid supplementation group and 13.4% (4849 events in 36 249 participants) in the control group. Two studies 26,37 observed a significantly reduced risk of CVD with supplementation of folic acid ( Figure 4) . One was the VITATOPS study, 37 which was conducted in 20 countries, and the other was the CSPPT trial, 26 (95% CI 0.90-0.99, P=0.02) from the random-effects model (Figure 4 (Table 3) . A larger magnitude of homocysteine reduction was associated with a greater reduction in the risk of CVD (change in homocysteine by 4 lmol/L in 10 RCTs: RR 1.01, 95% CI 0.96-1.06; P=0.67; by 4 to <5 lmol/L in 3 RCTs: RR 0.93, 95% CI 0.85-1.01; P=0.08; by ≥5 lmol/L in 5 RCTs: RR 0.82, 95% CI 0.71-0.94; P=0.005; P=0.009 for interaction). There was no significant difference in the intervention effect for other subgroups (Table 3) ; however, the benefits of folic acid supplementation for stroke and CVD appear to be stronger in Asian populations than in European or North American populations. We did not observe a significant difference of intervention effect according to the dosage of folic acid supplementation, as shown in Table 3 . We also examined the intervention effect stratified by average baseline age of participants and duration of followup but did not observe a clear pattern of intervention effect on CVD in the joint categories of these 2 variables (P=0.22 for interaction).
Assessment of Heterogeneity, Publication Bias, and Sensitivity Analysis
There was no evidence of between-study heterogeneity in any of the analyses (Figures 2-4) . Visual examination of Begg funnel plots for all analyses were moderately symmetrical, providing little evidence of publication bias. This was further supported by the results of the Egger test, which were nonsignificant in all analyses (all P>0.05) ( Figure 5 ). We did not observe any difference of intervention effects between trials with different risks of bias (Tables 3 and 4) .
In the sensitivity analysis, we did a metaregression analysis of the continuous variables that might potentially affect the treatment effects. We found no statistically significant doseresponse relationships between CVD outcomes and dosage of folic acid, baseline homocysteine levels, baseline mean age, and percentage of men in the trial, average follow-up time, and number of events in the study, suggesting that none of these factors had a significant impact on the overall metaanalysis (data not shown). We observed an inverse relation between degree of homocysteine reduction and intervention effect on CVD ( Figure 6 ) with a significant dose-response association (P=0.037 for metaregression after adjustment of baseline mean age and percentage of men in the trial). We did not, however, observe significant dose-response associations between degree of homocysteine reduction and risk of stroke or CHD. The exclusion of any single study from the analyses did not appreciably change the summary RRs and betweenstudy heterogeneity (Table 5 ).
Discussion
Summary of Main Results
In this meta-analysis we found a modest benefit of 10% reduced risk of stroke with folic acid supplementation compared with the control group. Folic acid supplementation also showed a small but significant benefit or 4% less risk of overall CVD events, with significant heterogeneity according to baseline folate levels, preexisting diseases, or the extent of H indicates high; L, low; M, medium. *Please refer to the Cochrane risk-of-bias tool for definitions and judgments for each item. The response to each item is "yes" (low risk of bias), "no" (high risk of bias), or "unclear" (insufficient information).
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Journal of the American Heart Association homocysteine reduction. No significant benefit or harm of folic acid supplementation on the risk of incident CHD was found.
Comparison With Other Meta-Analyses or Reviews
Compared with the most recent systematic reviews of folic acid supplementation and CVD risk, 20,23,52 we included 3 new trials [24] [25] [26] published during the 2013-2015 period and conducted in 4 countries with 22 510 more participants. Consequently, our comprehensive meta-analysis summarized the most up-to-date evidence. In addition, different from previous meta-analyses, we included all RCTs of folic acid supplementation and CVD without restrictions on the study sample size, treatment period, or preexisting disease status; however, we conducted stratified analyses to fully consider the impact of these factors on the intervention effect. Folic acid supplementation significantly reduced the risk of stroke by 18% in a meta-analysis in 2007 based on 8 RCTs with at least 10 stroke cases in each group and at least 6 months of follow-up. 22 After that, with more RCTs published, 10 more meta-analyses of folic acid supplementation and risk of stroke were published with different inclusion criteria. 20, 21, 23, [53] [54] [55] [56] [57] [58] [59] Although all of these meta-analyses suggested a potential beneficial effect of folic acid supplementation on stroke (RRs ranged from 0.82 to 0.96), 20, 21, 23, [53] [54] [55] [56] [57] [58] [59] none reached statistical significance, making the findings less conclusive. The results of our metaanalysis based on 20 RCTs provided similar results and extended the findings of previous meta-analyses, indicating a 10% significantly lower risk of stroke with folic acid supplementation.
Regarding the intervention effect of folic acid supplementation on risk of CHD, all meta-analyses, 23, 53, 56, 57, [59] [60] [61] including ours, reported a consistent nonsignificant intervention effect. The mechanism for the discrepancy in the folic acid intervention effect on stroke and CHD is unclear. Compared with CHD, which involves mainly large vessels, the underlying pathophysiological mechanisms for stroke are more heterogeneous and involve both cerebral large vessels and small vessels. As reported previously, elevated homocysteine was more likely a risk factor for small vessel diseases 62 ; therefore, the modest beneficial effect of homocysteine reduction by folic acid supplementation on stroke but not on CHD may be driven by its impact on reducing the atherosclerotic processes of small vessels. This hypothesis was indirectly supported by the stronger associations with stroke than CHD, with higher homocysteine levels observed in both prospective cohort and genetic studies.
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Comparison of RCTs With Observational and Genetic Studies
Compared with the results from prospective observations, 2,3,65 the magnitude of the intervention effect on stroke was much lower (only around half), and we did not find any significant effect on CHD. Many factors may contribute to this discrepancy in the results of observational studies and RCTs of folic acid supplementation. All participants in the RCTs had some preexisting diseases, including CVD, renal disease, atherosclerosis, or hypertension, and they were usually older, whereas participants in epidemiological studies were typically younger and healthier. In our subgroup analysis, the intervention effect of folic acid supplementation on both stroke and CVD was stronger among participants with neither CVD nor renal diseases; the magnitude of 20% reduced risk among this relatively healthy population was comparable to the findings from observational studies. Another explanation was that homocysteine reduction may be beneficial only at early stages of vascular disease manifestation and less effective in established CVD. Hodis and colleagues 48 observed that B vitamin supplementation significantly reduced the progression of early-stage subclinical atherosclerosis and carotid artery intima-media thickness but had no effect on the progression of markers of late-stage atherosclerosis. Patients with CVD tend to have more serious complications, and thus lifestyle modifications or medications, which may have stronger effects on CVD than homocysteine reduction, might have masked the effect of homocysteine reduction on risk of CVD. The HOPE2 trial observed that participants who did not receive lipid-lowering drugs had a larger treatment benefit, 66 whereas the VITATOPS trial found beneficial effects of B vitamins among patients without antiplatelet treatment. 15 It was also possible that the intervention effects of folic acid supplementation are modified by the specific genetic backgrounds of the populations. Previous genetic studies indicated that the MTHFR genotype was associated with a significant difference in homocysteine reduction following the same folic acid supplementation. 5, 6 Participants with different MTHFR genotypes also showed significantly different CVD risk 5, 6 ; however, only 3 RCTs measured the MTHFR genotypes of participants. 26 
Strengths and Limitations
Because we included only RCTs in our meta-analysis, our findings were unlikely to be affected by confounding factors. Other strengths included no evidence of heterogeneity and no detected publication bias. Our sensitivity analysis also showed minimal influence of any individual RCT on the combined results. Several limitations warrant consideration. First, like any meta-analysis, our findings may be constrained by the methodological rigor of the included studies. Although we assessed publication bias of the overall analysis with a funnel plot test, we could not completely exclude publication bias. Second, the included trials varied with respect to the characteristics of participants, the duration and intensity of treatment, and other design features; however, our stratified analyses and meta-regression analyses did not identify any factors that would have influenced the summary estimates of the meta-analysis. Third, the definitions of the CVD outcomes were somewhat heterogeneous in the selected trials, and that may influence the interpretation of the results; however, we examined the effect of folic acid supplementation on stroke and CHD separately, although there was no sufficient power to examine subtypes of stroke or CHD.
Compliance with treatment could be an important determinant of the outcome of RCTs. Although extent of homocysteine reduction could serve as a surrogate biomarker for the compliance of folic acid supplementation, not all RCTs provided data on homocysteine changes. Among a subgroup of RCTs with data of homocysteine changes, however, we observed a stronger intervention effect on CVD when the magnitude of homocysteine reduction was greater. Because the metaanalysis was based on the result at the study level instead of individual data, we could not evaluate the intervention effects according to individual homocysteine change or treatment compliance. We found a dose-response relationship between homocysteine reduction by folic acid supplementation and a reduction in risk of CVD but not of stroke. The lack of a doseresponse relationship between degree of homocysteine reduction and risk of stroke may not support a causal link between folic acid supplementation and stroke. A potential reason for the nonlinear relationship between homocysteine reduction and reduction in stroke risk could be related to threshold effects of high homocysteine levels on risk of stroke; a previous observational study observed significantly increased risk of stroke only in the group with serum homocysteine >18.6 mmol/L (upper quintile). 68 
Conclusion
Our findings, based on the most comprehensive and up-todate evidence, provide support for a modest benefit of folic acid supplementation for the prevention of stroke. There was a 10% reduced risk of stroke and a 4% reduced risk of overall CVD with folic acid supplementation. A greater benefit for CVD was observed among participants without preexisting CVD or with lower plasma folate levels at baseline and in studies with a larger decrease in homocysteine levels. We did not observe any significant benefit or harm with folic acid supplementation for the risk of CHD.
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